Anaphylm FDA Update: New Approval Date Set for 2027

Aquestive Therapeutics announces FDA acceptance of Anaphylm's NDA resubmission, with a March 16, 2027, action date for this potential anaphylaxis treatment.

Introduction

Aquestive Therapeutics has announced an important regulatory milestone for Anaphylm (dibutepinephrine), an investigational sublingual film being developed to treat severe allergic reactions, including anaphylaxis. On October 15, 2026, the company confirmed that the U.S. Food and Drug Administration (FDA) had accepted its resubmitted New Drug Application (NDA) as complete.

The FDA has assigned March 16, 2027, as the Prescription Drug User Fee Act (PDUFA) goal date for its decision. This development moves Anaphylm into another stage of regulatory review, although FDA approval has not yet been granted.

If approved, Anaphylm could offer a new way to administer emergency allergy medication without requiring an injection device. Its proposed delivery format may be particularly relevant to people who need to carry emergency treatment while attending school, working, travelling or participating in everyday activities.

FDA Accepts Anaphylm NDA Resubmission

Aquestive Therapeutics submitted its updated NDA to the FDA on September 16, 2026. The resubmission followed the company's August announcement of positive topline results from human factors and pharmacokinetic studies conducted to address concerns identified by the agency.

The FDA previously issued a Complete Response Letter (CRL) on January 30, 2026. A CRL means the agency could not approve the application in its submitted form and identified issues that needed to be addressed before approval could be considered.

Following the latest resubmission, the FDA classified the application as a Class 2 response. This classification generally provides a review period of six months for a resubmitted application, subject to applicable regulatory procedures.

The assigned PDUFA goal date of March 16, 2027, identifies the target date for FDA action. It does not guarantee that Anaphylm will receive approval by that date. The agency may approve the application, issue another response requesting additional information or take another regulatory action.

The latest announcement nevertheless represents a significant step forward for Aquestive Therapeutics as it continues working toward potential commercial availability.

What Is Anaphylm (Dibutepinephrine)?

Anaphylm is an investigational sublingual film developed by Aquestive Therapeutics for Type I allergic reactions, including anaphylaxis.

The product candidate uses a polymer matrix-based formulation containing dibutepinephrine, an epinephrine prodrug. It is designed to dissolve when placed under the tongue, allowing administration without water or swallowing.

According to the company, the film is approximately the size of a postage stamp and weighs less than an ounce. Its compact packaging is designed to fit conveniently into a wallet or phone case.

These features are intended to make the proposed treatment portable and practical for people who may need access to emergency allergy medication away from home.

However, Anaphylm remains an investigational product in the United States as of October 16, 2026. Its safety, effectiveness, approved instructions for use and availability remain subject to the FDA's review and final decision.

How Could Anaphylm Help Treat Severe Allergic Reactions?

Anaphylaxis is a serious, potentially life-threatening allergic reaction that can develop rapidly after exposure to a trigger such as certain foods, medications or insect stings.

Symptoms may include difficulty breathing, swelling of the tongue or throat, dizziness, a sudden drop in blood pressure, widespread hives and gastrointestinal symptoms. Severe reactions require immediate medical attention.

Epinephrine is the first-line medication for emergency treatment of anaphylaxis. It helps counter dangerous effects of the reaction, including airway narrowing and reduced blood pressure.

Currently available epinephrine treatments include injectable products, such as auto-injectors. These devices are effective emergency options, but some people may experience anxiety about injections or have concerns about carrying and using an injection device.

Anaphylm is being developed as a different delivery option. Its sublingual film format is intended to provide a compact, needle-free way to administer the investigational medication.

If the FDA approves the product, it could expand the available options for emergency allergy treatment. However, its clinical role and any potential advantages over existing treatments will depend on the FDA's assessment of the supporting evidence and the final product label.

Anaphylm should not be considered a replacement for currently prescribed emergency medication unless healthcare professionals advise otherwise after any relevant regulatory approval.

What Happens Next for Anaphylm?

The next major milestone is the FDA's target action date of March 16, 2027.

During the review, the agency will assess the resubmitted application and determine whether the available evidence supports approval. The review may include consideration of human factors data, pharmacokinetic findings, product administration and the company's responses to the previously identified deficiencies.

Human factors studies examine how people interact with a medical product and whether they can use it as intended. For an emergency treatment, usability is particularly important because a person may need to administer the medication during a stressful and time-sensitive situation.

Pharmacokinetic studies examine how a drug is absorbed, distributed, metabolised and eliminated by the body. These findings help regulators evaluate how a medicine behaves after administration.

Although Aquestive has reported positive topline results from the studies conducted to address the FDA's concerns, the agency must independently determine whether the full submission meets its regulatory requirements.

Patients, caregivers and healthcare professionals should therefore monitor official company announcements and FDA communications for further updates.

Aquestive Therapeutics Advances International Plans

Alongside its U.S. regulatory efforts, Aquestive Therapeutics is progressing with its international strategy for Anaphylm.

The company stated that it remains on track to complete a New Drug Submission to Health Canada during the fourth quarter of 2026.

A Canadian submission would represent a separate regulatory process. The timing and outcome of a Canadian review are not guaranteed by the progress of the U.S. application.

Aquestive is also preparing for a potential commercial launch in the United States, should the FDA approve Anaphylm. These preparations reflect the company's intention to be ready to introduce the product if it receives the necessary regulatory authorisation.

The company develops pharmaceutical products using oral film delivery technologies and is also pursuing other investigational treatments. Nevertheless, the future commercial prospects of Anaphylm will depend on regulatory decisions, product labelling, manufacturing readiness and market conditions.

Conclusion

The FDA's acceptance of the Anaphylm NDA resubmission marks a notable development in the search for additional treatment options for severe allergic reactions.

With a PDUFA goal date of March 16, 2027, Aquestive Therapeutics has a defined regulatory milestone ahead as it seeks approval for its dibutepinephrine sublingual film.

The product's compact, water-free delivery format could offer a new approach to emergency allergy medication if approved. However, Anaphylm has not yet received FDA approval, and its ultimate availability will depend on the outcome of the agency's review.

For now, people at risk of anaphylaxis should continue following their existing emergency treatment plans and consult healthcare professionals about appropriate medication options.

Medical Disclaimer

This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis or treatment recommendations. Anaphylm (dibutepinephrine) is an investigational product and has not been approved by the FDA as of October 16, 2026. Do not discontinue, delay or replace prescribed emergency allergy medication based on this article. Anaphylaxis is a medical emergency. Follow your prescribed emergency action plan, use your currently prescribed epinephrine treatment as directed and seek emergency medical assistance immediately if anaphylaxis is suspected.

Source

Aquestive Therapeutics, Inc., company announcement dated October 15, 2026, regarding FDA acceptance of the Anaphylm NDA resubmission and assignment of a March 16, 2027, PDUFA goal date.